Consensus Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Real-time Estimate Cboe BZX Other stock markets 03:37:59 2024-04-19 pm EDT			5-day change	1st Jan Change
2.02 ^USD	+8.60%		-2.91%	-16.67%

Mar. 25	Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	MT
Mar. 25	Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	CI

Evolution of the average Target Price on Emergent BioSolutions Inc.

Price target over the last 5 years

History of analyst recommendation changes

d7e4ef78b024a590d9f718fa1973c296.34KxNkvAcF-ZZyL8G9FyQ6nr4l9OKQuExpCQtUBzSdc.q9vZBHL4N2nWCW6XQYAHcf-ZhxUXTUTV973ixAIWcLGH7-leOJYaE-sLRQ~9509e208975a22bc9636fee44bc40963

Analyst Recommendations on Emergent BioSolutions Inc.

Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $5	Mar. 07	MT
Benchmark Downngrades Emergent Biosolutions to Hold From Buy	23-08-29	MT
Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $22	23-04-10	MT
JPMorgan Downgrades Emergent Biosolutions to Underweight From Neutral, Adjusts Price Target to $9 From $23	23-03-17	MT
Chardan Cuts Price Target on Emergent Biosolutions to $55 From $65 on Slower Revenue, Profitability Growth; Keeps Buy Rating	22-11-09	MT
Cowen Trims Emergent Biosolutions Price Target to $29 From $30, Maintains Market Perform Rating	22-09-12	MT
Wells Fargo Adjusts Emergent Biosolutions' Price Target to $38 from $46, Keeps Equalweight Rating	22-05-04	MT
Cantor Fitzgerald Cuts Emergent Biosolutions to Neutral From Overweight, Price Target to $33 From $55	22-05-02	MT
JPMorgan Trims Price Target for Emergent Biosolutions to $57 From $58, Maintains Neutral Rating	22-03-10	MT
Wells Fargo Adjusts Emergent Biosolutions' Price Target to $40 from $37, Keeps Equalweight Rating	22-03-10	MT
Benchmark Upgrades Emergent Biosolutions to Buy from Hold, Sets $77 Price Target	22-01-20	MT
Cantor Fitzgerald Adjusts Price Target on Emergent Biosolutions to $55 From $50, Reiterates Overweight Rating	22-01-20	MT
Chardan Adjusts Price Target on Emergent Biosolutions to $75 From $92, Maintains Buy Rating	21-11-10	MT
Benchmark Capital Downgrades Emergent Biosolutions to Hold From Buy	21-11-08	MT
EMERGENT BIOSOLUTIONS : Argus Research Downgrades Emergent Biosolutions to Hold From Buy	21-05-05	MT
EMERGENT BIOSOLUTIONS : Chardan Adjusts Price Target on Emergent Biosolutions to $92 From $112, Maintains Buy Rating	21-04-30	MT
EMERGENT BIOSOLUTIONS : Benchmark Adjusts Price Target on Emergent Biosolutions to $120 From $150, Maintains Buy Rating	21-04-30	MT
EMERGENT BIOSOLUTIONS : Guggenheim Adjusts Price Target on Emergent Biosolutions to $110 From $130, Maintains Buy Rating	21-04-14	MT
EMERGENT BIOSOLUTIONS : Benchmark Starts Emergent Biosolutions at Buy with $150 Price Target	21-04-07	MT
EMERGENT BIOSOLUTIONS : Chardan Upgrades Emergent BioSolutions to Buy From Neutral, Maintains $112 Price Target	21-02-24	MT
EMERGENT BIOSOLUTIONS : Chardan Downgrades Emergent Biosolutions to Neutral Rating From Buy; Price Target is $112	21-02-19	MT
EMERGENT BIOSOLUTIONS : Wells Fargo Downgrades Emergent Biosolutions to Equalweight from Overweight, Keeps $110 Price Target	21-01-08	MT
Emergent BioSolutions Inc. Provides Earnings Guidance for Third Quarter of 2020 and Raised Guidance for the Full Year of 2020	20-07-30	CI